Methods for Identifying Candidate Therapeutics for Ulcerative Colitis Using Single-Cell RNA Sequencing of Colonic Biopsy and Transcriptomic Reversal Scoring — Provisional Patent Specification

Read full text Summarise with VIRAT
Authors: Glen Charles Ritschel, Claude
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Provisional patent specification for USPTO filing. Discloses computational methods for drug repurposing in ulcerative colitis (UC) using single-cell RNA sequencing of colonic biopsies from 4 UC patients (inflamed), 4 UC self-controls (non-inflamed paired), and 4 healthy controls, variational autoencoder-based dimensionality reduction (scVI), Leiden clustering, Wilcoxon differential expression (UC vs HC primary, plus epithelial, immune, plasma cell, and pro-UC cluster subsets), and LINCS L1000 transcriptomic reversal scoring. Application to GSE231993 across 33 independent Enrichr queries identified 303 NOVEL_ALL candidates (56% of assessed compounds). Top candidates: AMG-232 (MDM2 inhibitor, priority 815,012), SAR405838 (MDM2 inhibitor, 787,447), R-547 (CDK inhibitor, 570,989), RG-7388 (MDM2 inhibitor, 466,170), GW-9662 (PPARγ antagonist, 377,523), TAK-733 (MEK1/2 inhibitor, 307,363), LXR-623 (LXR agonist, 49,934). Five MDM2 inhibitors in the top 15 — the densest single-mechanism cluster across the inventor's ten-pipeline series — implicate a p53-MDM2-colonocyte differentiation axis as a novel UC therapeutic target. R-547 achieves four-pipeline NOVEL_ALL consistency. Inventor: Glen Charles Ritschel, Ritschel Research, Tega Cay, SC. Micro-entity filing.

Fields of Study & Subjects

Inflammatory Bowel Disease Computational Drug Discovery Methods Single-cell and spatial transcriptomics

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
21 March 2026
Language
EN